5. IZZO NJ. SEIDMAN CEoCOLLINS S, COLUCCI WS. Alpha, adrenergic receptor mRNA level is regulated by norepinephrine in rabbit aortic smooth muscle cells. Proc Natl Acad Sci USA 1990 ;87:6268-71. 6 represent a class of compounds that are used extensively in clinical practice. These drugs competitively antagonize the activity of cyclooxygenase, reducing the synthesis of certain proinflammatory eicosanoids, most notably prostaglandins and thromboxane.' The NSAIDs are often used in the treatment of infants and children with bone and joint disorders, to reduce fever, and for the management of pain as either a primary or adjunctive analgesic. The increasing popularity of these drugs in pediatrics is evidenced by the recent availability of over-the-counter liquid formulations of ibuprofen and its active promotion as an alternative to aspirin. Despite this increasing availability to both medical and lay consumers, we should seriously reconsider the true therapeutic to toxic ratio of the routine use of these medicines over acetaminophen for antipyresis and the management of minor pain. t,2 However, the NSAIDs, and more specifically, intravenous indomethacin, have a definite role in neonatal practice. When used appropriately, intravenous indomethacin can promote the complete and permanent closure of an abnormal patent ductus arteriosus (PDA). A novel but rigorous strategy that incorporates patient-specific indomethacin pharmacokinetic monitoring has been described. When employed in a methodical manner, this approach can negate the need for surgical repair of a PDA in the majority of infants.'
Another potential therapeutic benefit of indomethacin administration to newborn infants is the prevention and/or treatment of neonatal intraventricular hemorrhage (IVH). Lamp and Reynolds succinctly review available literature that attempts to defme a role for indomethacin in neonatal IVH. This area of clinical therapeutics represents one of growing concern and interest in neonatology; as survival rates of smaller and smaller premature infants (i.e., newborns weighing <1000 g) increase, the prevention of diseases that cause long-term morbidity becomes an important frontier in therapeutics. Clearly, IVH is an important therapeutic challenge in these patients as it occurs in 40-60 percent of newborns weighing <1500 g, with the highest incidence occurring in the smallest babies.' The majority of these IVHs occur within the first three days of lifer' 50 percent usually occur on day 1, most often within the first 18 hours,' underscoring the importance of very early intervention. Neurologic sequelae following IVH can affect motor and mental functioning; the most severe sequelae occur in neonates experiencing the highest grade of IVH.6Hydrocephalus can also be a common complication.
As described in the review by Lamp and Reynolds, the etiology of IVH is believed to be multifactorial. Many of the factors involved are thought to exert their adverse effects, at least in part, by altering cerebral blood flow (CBF).4 Furthermore, Perlman et al. demonstrated a 91 percent incidence of IVH when CBF fluctuation occurred, versus 26 percent when CBF remained stable. Significant CBF fluctuation was noted in 13 percent of the 190 neonates studied. This incidence paralleled fluctuations in systemic blood pressure," Several drugs have been evaluated for their potential to prevent IVH; the common focus has been the theoretical mechanism(s) of decreased CBF or the reduction in CBF fluctuations. Recognition of the value of indomethacin therapy for the prevention of IVH is suggested in animal models of acute hemorrhage followed by volume expansion" and hypercarbia." Human studies are also generally favorable ( Table 1) . [10] [11] [12] [13] [14] In our opinion, a 20 percent reduction in grade II-IV IVH would appear to be therapeutically important. In review of the available studies, it is very important to discriminate patient subgroups and separate infants with grade I IVH from those who experience the more severe grade II-IV IVH, because the clinical outcome of a grade I IVH may be no different from that in control infants who did not experience an IVH.6 Five published articles meeting the criteria of pretreatment cranial ultrasound, indomethacin therapy started within 12 hours after birth, and posttreatment cranial ultrasound with results stratified to separate grade I from higher grades of IVH are shown in Table 1 . 10 • 14 All five studies show a favorable effect of indomethacin, with overall benefit appearing to result in a minimum of 40 percent reduction in IVH grades II-IV. In fact, several studies suggest that, even after hemorrhage, extension of a low-grade IVH may be prevented.w-' whereas, more advanced grades of IVH do not appear to worsen with indomethacin treatment.P-"
Complications associated with indomethacin therapy include temporary, reversible oliguria with diminished renal function, and excessive bleeding from puncture sites and the gastrointestinal tract. The incidence of these adverse effects varies; however, in our experience with over 100neonates treated with indomethacin for PDA closure, gastrointestinal bleeding has been rare and oliguria or diminished renal function has been reversible and relatively brief. The renal toxicity of indomethacin can be minimized by giving concurrent furosemide.P-" Whether furosemide-induced increases in prostaglandin synthesis would ablate the benefits of indomethacin in preventing IVH remains to be studied.
Indomethacin appears to be a reasonable consideration for IVH prevention, in particular in very high-risk neonates (i.e., those weighing <1500 g) experiencing fluctuating blood pressures and concurrent respiratory distress syndrome or recent asphyxia. Clearly more research is warranted, with future studies focusing on infants at the greatest risk for IVH. Study methodology should be rigorous enough to protect against patient selection bias, which could lead to a disproportioned enrollment of infants with widely fluctuating blood pressure in one group versus another. Protection against this possible bias would be an extremely important factor in our ability to discriminate a true effect of indomethacin. This was considered only in the studies performed by Ment et al. 10 ,1I Finally, one arm of any study should consider concurrent furosemide therapy to minimize toxicity.
It is important to recognize that multifactorial etiologies for IVH exist and any single intervention may result in only partial benefit. Nevertheless, a 20 percent reduction in grades III and IV IVH would profoundly affect the morbidity and mortality of many prematurely born infants. Any intervention as promising as indomethacin deserves to be aggressively pursued and studied. (13) aAll studies met criteria of: pre-and posttreatment cranial ultrasound, indomethacin therapy begun within 12 hours of birth, and grading of follow-up IVH data. IVH = intraventricular hemorrhage.
